Sunday, November 17, 2024
HomeTagsNominates

Nominates

Second Genome Nominates Development Candidate Targeting PAI-1/2 for the Treatment of Inflammatory Bowel Disease (IBD)

Second Genome, a biotechnology company that leverages its proprietary platform to discover and develop precision therapies and biomarkers, announced that the Company will advance...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics